Skip to content
Catalyst

Lacticaseibacillus rhamnosusFinding

Lacticaseibacillus rhamnosus has no detected effect on alanine aminotransferase

no difference foundModerate evidenceFinding

01 · The sentence it was drawn from

“ALT and AST decreased within the Del-Immune V® Extra group at month 3 (ALT: −5.88 U/L, 95% CI: −10.27 to −1.49; p = 0.011; AST: −2.78 U/L, 95% CI: −4.74 to −0.81; p = 0.007), but the between-group interaction tests were not significant (ALT p = 0.340; AST p = 0.111).”
Quoted verbatim from Lactobacillus rhamnosus Lysate for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial.
This finding among the 73 findings on its endpoint

Lacticaseibacillus rhamnosus

Alanine aminotransferase

no difference found

Who
Adults aged 18-70 with MASLD (BMI 25-39.9, FLI >60); standard lifestyle-modification programme and counselling in both arms; between-group time-by-treatment interaction over 6 months
Dose studied
100 mg twice daily for 12 weeks, then 3 months follow-up without treatment

Moderate evidencePMID 42942425 · 2026

02 · The study

Study
RCT
Duration
3 months

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M7G6G8V3W2XCG4H1WTB66W6P